Implementation of Jail and Prison-Based Medication Treatment for Opioid Use Disorder Programs: A Narrative Synthesis

Abstract

Provision of medications for opioid use disorder (MOUD) programs in carceral settings is critical to reducing overdose during the high-risk period following release from incarceration. Efforts to expand carceral MOUD programs have increased in recent years. We conducted a narrative review to synthesize evidence on the implementation of MOUD in U.S. carceral facilities. We analyzed 36 studies from 2019 to 2023 using the Exploration, Preparation, Implementation, Sustainment framework. Findings highlight that MOUD in carceral settings requires significant resources, infrastructure, and staffing. MOUD diversion is a common concern, with program responses varying widely. Stigma against MOUD remains a challenge, particularly when treating pregnant people with OUD. Effective coordination between carceral and community stakeholders is critical for MOUD implementation and continuity of treatment postrelease. COVID-19 spurred innovation, increasing telehealth in carceral MOUD programs. Future research should explore MOUD program transition from early adoption to wide-scale implementation, considering external factors, sustainability, and evolving policies.

Keywords

MOUD implementation medication opioid use disorder criminal justice system

Get full access to this article

View all access options for this article.

References

Aarons

G. A.

Hurlburt

Horwitz

S. M.

(2011). Advancing a conceptual model of evidence-based practice implementation in public service sectors. Administration and Policy in Mental Health, 38(1), 4–23. https://doi.org/10.1007/s10488-010-0327-7

Bandara

Kennedy-Hendricks

Merritt

Barry

C. L.

Saloner

(2021). Methadone and buprenorphine treatment in United States jails and prisons: Lessons from early adopters. Addiction, 116(12), 3473–3481. https://doi.org/10.1111/add.15565

Barnes

C. A.

Ponce

A. N.

Loewy

(2021). Recommendations to Improve Medication-Assisted Treatment Implementation in Correctional Health. Psychiatric Services, 72(2), 233–234. https://doi.org/10.1176/appi.ps.202000527

Binswanger

I. A.

Blatchford

P. J.

Mueller

S. R.

Stern

M. F.

(2013). Mortality after prison release: Opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Annals of Internal Medicine, 159(9), 592–600. https://doi.org/10.7326/0003-4819-159-9-201311050-00005

Binswanger

I. A.

Stern

M. F.

Deyo

R. A.

Heagerty

P. J.

Cheadle

Elmore

J. G.

Koepsell

T. D.

(2007). Release from prison—A high risk of death for former inmates. The New England Journal of Medicine, 356(2), 157–165. https://doi.org/10.1056/NEJMsa064115

Blue

T. R.

Fletcher

J. B.

Monico

L. B.

Gordon

M. S.

Schwartz

R. P.

Mitchell

S. G.

(2023). Jail and treatment staff attitudes regarding MOUDs before and after an implementation intervention. Journal of Offender Rehabilitation, 62(7), 411–426. https://doi.org/10.1080/10509674.2023.2246446

Booty

M. D.

Harp

Batty

Knudsen

H. K.

Staton

Oser

C. B.

(2023). Barriers and facilitators to the use of medication for opioid use disorder within the criminal justice system: Perspectives from clinicians. Journal of Substance Use and Addiction Treatment, 149, 209051. https://doi.org/10.1016/j.josat.2023.209051

Brinkley-Rubinstein

Peterson

Clarke

Macmadu

Truong

Pognon

Parker

Marshall

B. D. L.

Green

Martin

Stein

Rich

J. D.

(2019). The benefits and implementation challenges of the first state-wide comprehensive medication for addictions program in a unified jail and prison setting. Drug and Alcohol Dependence, 205, 107514. https://doi.org/10.1016/j.drugalcdep.2019.06.016

Cates

Brown

A. R.

(2023). Medications for opioid use disorder during incarceration and post-release outcomes. Health & Justice, 11(1), 4. https://doi.org/10.1186/s40352-023-00209-w

10.

Cheng

Badolato

Segoshi

McDonald

Malone

Vasudevan

Badiei

Sugarman

Macdonald

Mangat

Giftos

Lee

J. D.

Tofighi

(2022). Perceptions and experiences toward extended-release buprenorphine among persons leaving jail with opioid use disorders before and during COVID-19: An in-depth qualitative study. Addiction Science & Clinical Practice, 17(1), 4. https://doi.org/10.1186/s13722-022-00288-4

11.

Clark

K. J.

Vechinski

Molfenter

Taxman

F. S.

(2023). Cascade of care in the legal system: Best practices and goals for agencies providing care to patients concurrently navigating substance use disorders and criminal legal involvement. Journal of Drug Issues, 55(1), 64–88. https://doi.org/10.1177/00220426231196304

12.

Donelan

C. J.

Hayes

Potee

R. A.

Schwartz

Evans

E. A.

(2021). COVID-19 and treating incarcerated populations for opioid use disorder. Journal of Substance Abuse Treatment, 124, 108216. https://doi.org/10.1016/j.jsat.2020.108216

13.

Duncan

Sanders

Schiff

Winkelman

T. N. A.

(2021). Adaptations to jail-based buprenorphine treatment during the COVID-19 pandemic. Journal of Substance Abuse Treatment, 121, 108161. https://doi.org/10.1016/j.jsat.2020.108161

14.

Evans

E. A.

Pivovarova

Stopka

T. J.

Santelices

Ferguson

W. J.

Friedmann

P. D.

(2022). Uncommon and preventable: Perceptions of diversion of medication for opioid use disorder in jail. Journal of Substance Abuse Treatment, 138, 108746. https://doi.org/10.1016/j.jsat.2022.108746

15.

Evans

E. A.

Wilson

Friedmann

P. D.

(2022). Recidivism and mortality after in-jail buprenorphine treatment for opioid use disorder. Drug and Alcohol Dependence, 231, 109254. https://doi.org/10.1016/j.drugalcdep.2021.109254

16.

Ferguson

W. J.

Johnston

Clarke

J. G.

Koutoujian

P. J.

Maurer

Gallagher

White

Nickl

Taxman

F. S.

(2019). Advancing the implementation and sustainment of medication assisted treatment for opioid use disorders in prisons and jails. Health & Justice, 7(1), 19. https://doi.org/10.1186/s40352-019-0100-2

17.

Flanagan Balawajder

Ducharme

Taylor

B. G.

Lamuda

P. A.

Kolak

Friedmann

P. D.

Pollack

H. A.

Schneider

J. A

. (2024). Factors associated with the availability of medications for opioid use disorder in US jails. JAMA Network Open, 7(9), e2434704. https://doi.org/10.1001/jamanetworkopen.2024.34704

18.

Funk

Ishee

Paluzzi

(2024, February 29). SAMHSA final rule codifies opioid treatment program telehealth and take-home medication flexibilities. Insights & Resources. Goodwin. https://www.goodwinlaw.com/en/insights/publications/2024/02/alerts-otherindustries-hltc-samhsa-final-rule-codifies-opioid-treatment

19.

Grella

C. E.

Ostile

Scott

C. K.

Dennis

Carnavale

(2020). A scoping review of barriers and facilitators to implementation of medications for treatment of opioid use disorder within the criminal justice system. The International Journal on Drug Policy, 81, 102768. https://doi.org/10.1016/j.drugpo.2020.102768

20.

Grella

C. E.

Scott

C. K.

Dennis

M. L.

LaVallee

R. A.

(2023). Access to services for pregnant people with opioid use disorder in jails in the United States. Journal of Correctional Health Care: The Official Journal of the National Commission on Correctional Health Care, 29(4), 299–307. https://doi.org/10.1089/jchc.22.03.0023

21.

Hanna

Kubiak

Pasman

Gaba

Andre

Smelson

Pinals

D. A.

(2020). Evaluating the implementation of a prisoner re-entry initiative for individuals with opioid use and mental health disorders: Application of the consolidated framework for implementation research in a cross-system initiative. Journal of Substance Abuse Treatment, 108, 104–114. https://doi.org/10.1016/j.jsat.2019.06.012

22.

Harrington

Bailey

Delorme

Hano

Evans

E. A.

(2023). “And then COVID hits”: A qualitative study of how jails adapted services to treat opioid use disorder during COVID-19. Substance Use & Misuse, 58(2), 266–274. https://doi.org/10.1080/10826084.2022.2155480

23.

Hartung

D. M.

McCracken

C. M.

Nguyen

Kempany

Waddell

E. N.

(2023). Fatal and nonfatal opioid overdose risk following release from prison: A retrospective cohort study using linked administrative data. Journal of Substance Use and Addiction Treatment, 147, 208971. https://doi.org/10.1016/j.josat.2023.208971

24.

Health Management Associates. (2023). Maryland learning collaborative to support opioid use disorder examinations and treatment act and Medication Assisted Treatment (MAT) implementation for justice-involved populations. https://gocpp.maryland.gov/wp-content/uploads/Maryland-Learning-Collaborative-20230925-1.pdf

25.

Hinton

Pillai

Published

A. D.

(2024, August 19). Section 1115 Waiver watch: Medicaid pre-release services for people who are incarcerated. KFF. https://www.kff.org/medicaid/issue-brief/section-1115-waiver-watch-medicaid-pre-release-services-for-people-who-are-incarcerated/

26.

Homans

Allen

D. M.

(2023). A review of Medication Assisted Treatment (MAT) in United States jails and prisons. https://cchcs.ca.gov/wp-content/uploads/sites/60/MAT-in-United-States-Jails-and-Prisons-Final.pdf

27.

Kang

Bailey

Napoleon

Martin

(2023). Contextualizing medications for opioid use disorder and peer support service provision in the probation system with implementation science. Research Square. https://doi.org/10.21203/rs.3.rs-3607705/v1

28.

Kang-Brown

Zhang

(2024). People in jail and prison in 2024. https://vera-institute.files.svdcdn.com/production/downloads/publications/People-in-Jail-and-Prison-in-2024-Full-Reportpdf.pdf

29.

Kaplowitz

Truong

A. Q.

Berk

Martin

R. A.

Clarke

J. G.

Wieck

Rich

Brinkley-Rubinstein

(2022). Treatment preference for opioid use disorder among people who are incarcerated. Journal of Substance Abuse Treatment, 137, 108690. https://doi.org/10.1016/j.jsat.2021.108690

30.

Kaplowitz

Truong

A. Q.

Macmadu

Berk

Martin

Burke

Rich

J. D.

Brinkley-Rubinstein

(2023). Anticipated barriers to sustained engagement in treatment with medications for opioid use disorder after release from incarceration. Journal of Addiction Medicine, 17(1), 54–59. https://doi.org/10.1097/ADM.0000000000001029

31.

Kawasaki

Hwang

Buckner

Francis

Huffnagle

Kraschnewski

Vulgamore

Lucas

Barbour

Crawford

Thomas

Fuller

Meyers

Swartzentruber

Levine

(2022). Collaborative health systems ECHO: The use of a tele-education platform to facilitate communication and collaboration with recipients of state targeted response funds in Pennsylvania. Substance Abuse, 43(1), 892–900. https://doi.org/10.1080/08897077.2021.2007519

32.

King

Kramer

Latkin

Sufrin

(2021). Access to treatment for pregnant incarcerated people with opioid use disorder: Perspectives from community opioid treatment providers. Journal of Substance Abuse Treatment, 126, 108338. https://doi.org/10.1016/j.jsat.2021.108338

33.

Klemperer

E. M.

Wreschnig

Crocker

King-Mohr

Ramniceanu

Brooklyn

J. R.

Peck

K. R.

Rawson

R. A.

Evans

E. A.

(2023). The impact of the implementation of medication for opioid use disorder and COVID-19 in a statewide correctional system on treatment engagement, postrelease continuation of care, and overdose. Journal of Substance Use and Addiction Treatment, 152, 209103. https://doi.org/10.1016/j.josat.2023.209103

34.

Krawczyk

Bandara

Merritt

Shah

Duncan

McEntee

Schiff

Ahmad

N. J.

Whaley

Latimore

Saloner

(2022). Jail-based treatment for opioid use disorder in the era of bail reform: A qualitative study of barriers and facilitators to implementation of a state-wide medication treatment initiative. Addiction Science & Clinical Practice, 17(1), 30. https://doi.org/10.1186/s13722-022-00313-6

35.

Lam

J. A.

Lee

H. I. S.

Truong

A. Q.

Macmadu

Clarke

J. G.

Rich

Brockmann

(2019). Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting. Journal of Substance Abuse Treatment, 104, 28–33. https://doi.org/10.1016/j.jsat.2019.06.001

36.

Ludwig

Monico

L. B.

Blue

Gordon

M. S.

Schwartz

R. P.

Mitchell

S. G.

(2022). Development and use of a checklist for the implementation of medication for opioid use disorder in jails. Implementation Research and Practice, 3, 26334895221101214. https://doi.org/10.1177/26334895221101214

37.

MacArthur

G. J.

Minozzi

Martin

Vickerman

Deren

Bruneau

Degenhardt

Hickman

(2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. BMJ, 345, Article e5945. https://doi.org/10.1136/bmj.e5945

38.

Macmadu

Goedel

W. C.

Adams

J. W.

Brinkley-Rubinstein

Green

T. C.

Clarke

J. G.

Martin

R. A.

Rich

J. D.

Marshall

B. D. L.

(2020). Estimating the impact of wide scale uptake of screening and medications for opioid use disorder in US prisons and jails. Drug and Alcohol Dependence, 208, 107858. https://doi.org/10.1016/j.drugalcdep.2020.107858

39.

Martin

Phillips

M. A.

Saxon

Love

Cessna

Woodard

D. L.

Page

Curry

Paone

Pennington-Stallcup

Riley

(2021). Recovery support specialists inside the jail: A program description of treatment engagement for opioid use disorder. International Journal of Prisoner Health, 17(4), 497–508. https://doi.org/10.1108/IJPH-12-2020-0102

40.

Maruschak

L. M.

Minton

T. D.

Zeng

(2023). Opioid use disorder screening and treatment in local jails, 2019. Bureau of Justice Statistics. https://bjs.ojp.gov/library/publications/opioid-use-disorder-screening-and-treatment-local-jails-2019

41.

Matsumoto

Santelices

Evans

E. A.

Pivovarova

Stopka

T. J.

Ferguson

W. J.

Friedmann

P. D.

(2022). Jail-based reentry programming to support continued treatment with medications for opioid use disorder: Qualitative perspectives and experiences among jail staff in Massachusetts. The International Journal on Drug Policy, 109, 103823. https://doi.org/10.1016/j.drugpo.2022.103823

42.

National Academies of Sciences, Engineering, and Medicine, Health and Medicine Division, Board on Health Sciences Policy, Committee on Medication-Assisted Treatment for Opioid, Mancher

Leshner

A. I

. (2019). The Effectiveness of Medication-Based Treatment for Opioid Use Disorder. Medications for Opioid Use Disorder Save Lives. National Academies Press (US). https://www.ncbi.nlm.nih.gov/books/NBK541393/

43.

National Cancer Institute. (n.d.). About implementation science. NIH National Cancer Institute. https://cancercontrol.cancer.gov/is/about#:~:text=Implementation%20science%20(IS)%20is%20the,our%20impact%20on%20population%20health

44.

National Commission on Correctional Health Care & National Sheriffs’ Association. (2025). Jail guidelines for the medical treatment of substance use disorders 2025. National Commission on Correctional Health Care. https://www.ncchc.org/jail-based-mat/

45.

New York State Department of Health. (2022). Medication for Opioid Use Disorder (MOUD): Correctional health implementation toolkit. https://www.health.ny.gov/diseases/aids/providers/prevention/harm_reduction/buprenorphine/docs/moud_toolkit.pdf

46.

Office of Public Affairs. (2022, April 5). Justice department issues guidance on protections for people with opioid use disorder under the Americans with Disabilities Act. United States Department of Justice. https://www.justice.gov/archives/opa/pr/justice-department-issues-guidance-protections-people-opioid-use-disorder-under-americans

47.

Pivovarova

Evans

E. A.

Stopka

T. J.

Santelices

Ferguson

W. J.

Friedmann

P. D.

(2022). Legislatively mandated implementation of medications for opioid use disorders in jails: A qualitative study of clinical, correctional, and jail administrator perspectives. Drug and Alcohol Dependence, 234, 109394. https://doi.org/10.1016/j.drugalcdep.2022.109394

48.

Pivovarova

Taxman

F. S.

Boland

A. K.

Smelson

D. A.

Lemon

S. C.

Friedmann

P. D.

(2023). Facilitators and barriers to collaboration between drug courts and community-based medication for opioid use disorder providers. Journal of Substance Use and Addiction Treatment, 147, 208950. https://doi.org/10.1016/j.josat.2022.208950

49.

Pourtaher

Gelberg

K. H.

Fallico

Ellendon

(2023). Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation. Journal of Substance Use and Addiction Treatment, 161, 209248. https://doi.org/10.1016/j.josat.2023.209248

50.

Ranapurwala

S. I.

Shanahan

M. E.

Alexandridis

A. A.

Proescholdbell

S. K.

Naumann

R. B.

Edwards

Marshall

S. W.

(2018). Opioid overdose mortality among former North Carolina inmates: 2000-2015. American Journal of Public Health, 108(9), 1207–1213. https://doi.org/10.2105/AJPH.2018.304514

51.

Roth

Doolittle

Chhean

Tewarson

(2025, January 21). Update on Medicaid section 1115 Waivers. NASHP. https://nashp.org/january-2025-update-on-medicaid-section-1115-waivers/

52.

Ryan

D. A.

Montoya

I. D.

Koutoujian

P. J.

Siddiqi

Hayes

Jeng

P. J.

Cadet

McCollister

K. E.

Murphy

S. M.

(2023). Budget impact tool for the incorporation of medications for opioid use disorder into jail/prison facilities. Journal of Substance Use and Addiction Treatment, 146, 208943. https://doi.org/10.1016/j.josat.2022.208943

53.

Saunders

E. C.

Satcher

M. F.

Monico

L. B.

McDonald

R. D.

Springer

S. A.

Farabee

Gryczynski

Nyaku

Reeves

Kunkel

L. E.

Schultheis

A. M.

Schwartz

R. P.

Lee

J. D.

Marsch

L. A.

Waddell

E. N.

(2022). The impact of COVID-19 on the treatment of opioid use disorder in carceral facilities: A cross-sectional study. Health & Justice, 10(1), 35. https://doi.org/10.1186/s40352-022-00199-1

54.

Sawyer

Wagner

(2025, March 11). Mass incarceration: The whole pie 2025. Prison and Policy Initiative. https://www.prisonpolicy.org/reports/pie2025.html

55.

Scott

C. K.

Grella

C. E.

Dennis

M. L.

Carnevale

LaVallee

(2022). Availability of best practices for opioid use disorder in jails and related training and resource needs: Findings from a national interview study of jails in heavily impacted counties in the U.S. Health & Justice, 10(1), 36. https://doi.org/10.1186/s40352-022-00197-3

56.

Solomon

A. L.

Moore

K. F.

McLearen

A. M.

, & Office of Justice Programs Bureau of Justice Assistance. (2023). Guidelines for managing substance withdrawal in jails: A tool for local government officials, jail administrators, correctional officers, and health care professionals. U.S. Department of Justice Office of Justice Programs. https://bja.ojp.gov/doc/guidelines-managing-substance-withdrawal-jails.pdf

57.

Staton

Pike

Levi

Lofwall

(2023). The importance of justice and health care partnerships in MOUD feasibility trials. Journal of Social Work Practice in the Addictions. https://www.tandfonline.com/doi/abs/10.1080/1533256X.2023.2178119

58.

Staton

Pike

Tillson

Lofwall

M. R.

(2023). Facilitating factors and barriers for use of medications to treat opioid use disorder (MOUD) among justice-involved individuals in rural Appalachia. Journal of Community Psychology, 52(8), 997–1014. https://doi.org/10.1002/jcop.23029

59.

Stopka

T. J.

Rottapel

R. E.

Ferguson

W. J.

Pivovarova

Toro-Mejias

L. D.

Friedmann

P. D.

Evans

E. A.

(2022). Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers. The International Journal on Drug Policy, 110, 103803. https://doi.org/10.1016/j.drugpo.2022.103803

60.

Substance Abuse and Mental Health Services Administration. (2019, July). Use of medication-assisted treatment for opioid use disorder in criminal justice settings. SAMHSA Library. https://library.samhsa.gov/product/Use-of-Medication-Assisted-Treatment-for-Opioid-Use-Disorder-in-Criminal-Justice-Settings/PEP19-MATUSECJS

61.

Sufrin

Kramer

C. T.

Terplan

Fiscella

Olson

Voegtline

Latkin

(2023). Availability of medications for opioid use disorder in U.S. jails. Journal of General Internal Medicine, 38(6), 1573–1575. https://doi.org/10.1007/s11606-022-07812-x

62.

Sufrin

Kramer

C. T.

Terplan

Fiscella

Olson

Voegtline

Latkin

(2022). Availability of medications for the treatment of opioid use disorder among pregnant and postpartum individuals in US jails. JAMA Network Open, 5(1), e2144369. https://doi.org/10.1001/jamanetworkopen.2021.44369

63.

Sufrin

Sutherland

Beal

Terplan

Latkin

Clarke

J. G.

(2020). Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: Results from a national surveillance study. Addiction, 115(11), 2057–2065. https://doi.org/10.1111/add.15030

64.

Teixeira da Silva

O’Brien

Wachino

(2023). Recommendations for Medicaid coverage of opioid use disorder services in jails and prisons. Viaduct Consulting. https://healthandreentryproject.org/wp-content/uploads/2023/10/Recommendations-for-Medicaid-Coverage-of-OUD-Services-in-Jails-and-Prison.pdf

65.

Thakrar

A. P.

Alexander

G. C.

Saloner

(2021). Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. JAMA Network Open, 4(12), e2138807. https://doi.org/10.1001/jamanetworkopen.2021.38807

66.

Thomas

Singer

Kopak

(2023). Receptivity to Jail-based medication for opioid use disorder among rural detention Administrators. Corrections, 9(4), 517–535. https://doi.org/10.1080/23774657.2023.2278195

67.

Treitler

P. C.

Enich

Reeves

Crystal

(2022). Medications for opioid use disorder in state prisons: Perspectives of formerly incarcerated persons. Substance Abuse, 43(1), 964–971. https://doi.org/10.1080/08897077.2022.2060448

68.

Victor

Lee

Pozo

del Silverstein

Zettner

Cason

Ray

(2022). Medications for opioid use disorder in the criminal/legal system: Knowledge, beliefs, and attitudes among rural community-based stakeholders. Journal of Drug Issues, 52(3), 389–405. https://doi.org/10.1177/00220426221076800

69.

Whaley

Bandara

Taylor

Krawczyk

(2023). Expanding buprenorphine in U.S. jails: One county’s response to addressing the fears of diversion. Journal of Substance Use and Addiction Treatment, 146, 208944. https://doi.org/10.1016/j.josat.2022.208944

70.

Zielinski

M. J.

Allison

M. K.

Brinkley-Rubinstein

Curran

Zaller

N. D.

Kirchner

J. A. E.

(2020). Making change happen in criminal justice settings: Leveraging implementation science to improve mental health care. Health & Justice, 8(1), 21. https://doi.org/10.1186/s40352-020-00122-6

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.27 MB